AARD logo

AARDVARK THERAPEUTICS INC

AARDNASDAQ
🏆 #4036 by market capUS Equity
$5.37▲ $0.10 (+1.80%)
After hours · at close
🔔
Track AARD
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.8%
7d▼ 6.5%
14d▲ 6.4%
30d▼ 6.0%
ytd▼ 59.0%
1y▼ 60.7%
🏦Market Cap
$117M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
84
Good

Trading Snapshot

Day Range
$5.29 – $5.39
52-Week Range
$3.35 – $17.94
Volume
$5.83B
Avg Volume
$4.21B
Shares Outstanding
21.9M
Next Earnings
Nov 5, 2026

Fundamentals Snapshot

Annual Revenue
$40M
Last Q Revenue
$10M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-3.21
Dividend Yield
—
Dilution (1yr)
+0.6%

Why Investors Own AARD

  • ✓High-growth profile — revenue up +49.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 62% gross margin and 19% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AARD logo

AARDVARK THERAPEUTICS INC

AARD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$63M▲ +175.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$54M▲ +198.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
21.8M▲ +0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$47M▼ −$14M YoY
StockOtter · stockotter.space

About AARDVARK THERAPEUTICS INC

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
84/100

Analyst Price Target

ⓘ
Average Target
$7.09
▲ +32.1% Upside
High Target$8.06
Low Target$5.95
Based on 23 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

AARDVARK THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift AARD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

AARDVARK THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.